academic article

• Identifying dynamic functional connectivity biomarkers using GIG-ICA: Application to schizophrenia, schizoaffective disorder, and psychotic bipolar disorder..  Human brain mapping.  38:2683-2708. 2017
• Magnetoencephalographic and functional MRI connectomics in schizophrenia via intra- and inter-network connectivity..  NeuroImage.  145:96-106. 2017
• Predicting individualized clinical measures by a generalized prediction framework and multimodal fusion of MRI data..  NeuroImage.  145:218-229. 2017
• Socio-neuro risk factors for suicidal behavior in criminal offenders with psychotic disorders..  Social cognitive and affective neuroscience.  12:70-80. 2017
• Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study..  Psychiatric services (Washington, D.C.).  :-. 2016
• Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample..  Schizophrenia bulletin.  :-. 2016
• Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia..  Schizophrenia bulletin.  :-. 2016
• Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia..  Translational psychiatry.  6:-. 2016
• Neuropsychological profile in adult schizophrenia measured with the CMINDS..  Psychiatry research.  230:826-834. 2015
• Hemodynamic response function abnormalities in schizophrenia during a multisensory detection task..  Human brain mapping.  :-. 2015
• An fMRI study of multimodal selective attention in schizophrenia..  The British journal of psychiatry : the journal of mental science.  :-. 2015
• MIR137HG risk variant rs1625579 genotype is related to corpus callosum volume in schizophrenia..  Neuroscience letters.  602:44-49. 2015
• Spatial Variance in Resting fMRI Networks of Schizophrenia Patients: An Independent Vector Analysis..  Schizophrenia bulletin.  :-. 2015
• Relating Intrinsic Low Frequency Bold Cortical Oscillations to Cognition in Schizophrenia..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  :-. 2015
• Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study..  Schizophrenia bulletin.  41:449-459. 2015
• Reproducibility of phase rotation stimulated echo acquisition mode at 3T in schizophrenia: Emphasis on glutamine..  Magnetic resonance in medicine.  :-. 2015
• The Paradoxical Relationship Between White Matter, Psychopathology and Cognition in Schizophrenia: A Diffusion Tensor and Proton Spectroscopic Imaging Study..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  :-. 2015
• In Search of Multimodal Neuroimaging Biomarkers of Cognitive Deficits in Schizophrenia..  Biological psychiatry.  :-. 2015
• Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia..  Schizophrenia bulletin.  41:223-232. 2015
• Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis..  Schizophrenia bulletin.  :-. 2014
• Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia..  NeuroImage.  97:117-126. 2014
• Genetic influences on cognitive endophenotypes in schizophrenia..  Schizophrenia research.  156:71-75. 2014
• The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data..  Brain imaging and behavior.  8:153-182. 2014
• A multi-scanner study of subcortical brain volume abnormalities in schizophrenia..  Psychiatry research.  222:10-16. 2014
• The impact of parent socio-economic status on executive functioning and cortical morphology in individuals with schizophrenia and healthy controls. 2014
• Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T..  JAMA psychiatry.  71:265-272. 2014
• Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation..  Biological psychiatry.  75:398-405. 2014
• A robust classifier to distinguish noise from fMRI independent components. 2014
• Converting positive and negative symptom scores between PANSS and SAPS/SANS..  Schizophrenia research.  152:289-294. 2014
• Hippocampal structural and functional changes associated with electroconvulsive therapy response..  Translational psychiatry.  4:-. 2014
• Methylation patterns in whole blood correlate with symptoms in schizophrenia patients..  Schizophrenia bulletin.  40:769-776. 2014
• Multisensory stimuli elicit altered oscillatory brain responses at gamma frequencies in patients with schizophrenia..  Frontiers in human neuroscience.  8:-. 2014
• Guided exploration of genomic risk for gray matter abnormalities in schizophrenia using parallel independent component analysis with reference..  NeuroImage.  83:384-396. 2013
• Using joint ICA to link function and structure using MEG and DTI in schizophrenia..  NeuroImage.  83:418-430. 2013
• Attenuated psychosis syndrome in DSM-5..  Schizophrenia research.  150:31-35. 2013
• Catatonia in DSM-5..  Schizophrenia research.  150:26-30. 2013
• Definition and description of schizophrenia in the DSM-5..  Schizophrenia research.  150:3-10. 2013
• Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5..  Schizophrenia research.  150:15-20. 2013
• Schizoaffective Disorder in the DSM-5..  Schizophrenia research.  150:21-25. 2013
• Structure of the psychotic disorders classification in DSM-5..  Schizophrenia research.  150:11-14. 2013
• Functional imaging of the hemodynamic sensory gating response in schizophrenia..  Human brain mapping.  34:2302-2312. 2013
• Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update..  Dialogues in clinical neuroscience.  15:329-337. 2013
• High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study..  Journal of clinical psychopharmacology.  33:485-490. 2013
• The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia..  Neuroinformatics.  11:367-388. 2013
• The impact of copy number deletions on general cognitive ability and ventricle size in patients with schizophrenia and healthy control subjects..  Biological psychiatry.  73:540-545. 2013
• A multi-site resting state fMRI study on the amplitude of low frequency fluctuations in schizophrenia..  Frontiers in neuroscience.  7:-. 2013
• Combination of Resting State fMRI, DTI, and sMRI Data to Discriminate Schizophrenia by N-way MCCA + jICA..  Frontiers in human neuroscience.  7:-. 2013
• Electroconvulsive therapy response in major depressive disorder: a pilot functional network connectivity resting state FMRI investigation..  Frontiers in psychiatry.  4:-. 2013
• Frontal and superior temporal auditory processing abnormalities in schizophrenia..  NeuroImage. Clinical.  2:695-702. 2013
• Frontotemporal anatomical connectivity and working-relational memory performance predict everyday functioning in schizophrenia..  Psychophysiology.  49:1340-1352. 2012
• Heritability of multivariate gray matter measures in schizophrenia..  Twin research and human genetics : the official journal of the International Society for Twin Studies.  15:324-335. 2012
• Reliability of the amplitude of low-frequency fluctuations in resting state fMRI in chronic schizophrenia..  Psychiatry research.  201:253-255. 2012
• Cigarette smoking and white matter microstructure in schizophrenia..  Psychiatry research.  201:152-158. 2012
• Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy..  Neurochemistry international.  61:128-131. 2012
• Bilateral hippocampal dysfunction in schizophrenia..  NeuroImage.  58:1158-1168. 2011
• Unisensory processing and multisensory integration in schizophrenia: a high-density electrical mapping study..  Neuropsychologia.  49:3178-3187. 2011
• A baseline for the multivariate comparison of resting-state networks..  Frontiers in systems neuroscience.  5:-. 2011
• Antipsychotic dose and diminished neural modulation: a multi-site fMRI study..  Progress in neuro-psychopharmacology & biological psychiatry.  35:473-482. 2011
• Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study..  Schizophrenia bulletin.  37:222-232. 2011
• Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla..  Biological psychiatry.  69:19-27. 2011
• 1H-MRS at 4 tesla in minimally treated early schizophrenia..  Molecular psychiatry.  15:629-636. 2010
• Catatonia in the DSM--shall we move or not?.  Schizophrenia bulletin.  36:205-207. 2010
• Decreased default mode neural modulation with age in schizophrenia..  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.  18:897-907. 2010
• The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11. 2009
• Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  33:2456-2466. 2008
• Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients..  The American journal of psychiatry.  165:1594-1603. 2008
• Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla..  Magnetic resonance in medicine.  58:236-244. 2007
• Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  31:751-756. 2006
• What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update..  Current opinion in psychiatry.  19:135-139. 2006
• Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia..  The American journal of psychiatry.  163:1829-1831. 2006
• Cross-modal generality of the gating deficit..  Psychophysiology.  42:318-327. 2005
• Selective cognitive impairments associated with NMDA receptor blockade in humans..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  30:633-639. 2005
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study..  The American journal of psychiatry.  162:394-396. 2005
• Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels..  Schizophrenia research.  66:31-39. 2004
• Integrated treatment of schizophrenia..  Psychiatric services (Washington, D.C.).  54:1499-1507. 2003
• Reproducibility of 1H-MRS measurements in schizophrenic patients..  Magnetic resonance in medicine.  50:704-707. 2003
• Lateralization of auditory sensory gating and neuropsychological dysfunction in schizophrenia..  The American journal of psychiatry.  160:1595-1605. 2003
• Predicting EEG responses using MEG sources in superior temporal gyrus reveals source asynchrony in patients with schizophrenia..  Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology.  114:835-850. 2003
• Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia..  The Psychiatric clinics of North America.  26:191-211. 2003
• Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients..  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.  28:527-529. 2003
• Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure..  Schizophrenia research.  58:313-321. 2002
• High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia..  The American journal of psychiatry.  159:130-133. 2002
• Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia..  Psychiatry research.  107:135-149. 2001
• Medication treatments for schizophrenia: translating research findings into better outcomes..  Journal of psychiatric practice.  7:260-265. 2001
• Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia..  Seminars in clinical neuropsychiatry.  6:121-130. 2001
• The patient with first episode psychosis..  Journal of psychiatric practice.  7:123-132. 2001
• The psychosocial treatment of schizophrenia: an update..  The American journal of psychiatry.  158:163-175. 2001
• Commentary: can intensive psychosocial treatments make a difference in a time of atypical antipsychotics and managed care?.  Schizophrenia bulletin.  26:141-144. 2000
• A critical review of research on psychosocial treatment of schizophrenia..  Biological psychiatry.  46:1409-1417. 1999
• Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping..  The Journal of nervous and mental disease.  187:72-79. 1999
• Schizophrenia: improving outcome..  Harvard review of psychiatry.  6:229-240. 1999
• Visual information-processing impairments in deficit and nondeficit schizophrenia..  The American journal of psychiatry.  154:647-654. 1997
• Differential effect of clozapine on weight: a controlled study..  The American journal of psychiatry.  153:817-819. 1996
• The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs..  Schizophrenia research.  20:79-90. 1996
• Neuroleptic-induced emesis: a new indication for clozapine?.  Biological psychiatry.  38:194-195. 1995
• Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia..  Biological psychiatry.  38:64-67. 1995
• Prodromal symptoms vs. early warning signs and clinical action in schizophrenia..  Schizophrenia bulletin.  21:553-559. 1995